[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"@RaajitRampal @clinadvances @doctorpemm @TaniaJain11 @Medscape @MKremyanskaya @doclucchesi @harrisoncn1 @VasNarasimhan @antengene @EricTokat @IcahnMountSinai @HealthTree @traviscooper93 @mpnadvocacy @GabyHobbs @Stemline @Blood_Cancers @SocietyofHemOnc @mpdrc @mlieducation @MDmasarova @JamesPharma $GSK's momelotinib sales slowing down () in Q3 $146m vs. Q2 $138m vs. Q1 $112m $KPTI /287"
X Link @kinatsofrim 2025-10-29T15:48Z XXX followers, XXX engagements
"As for $GSK's IDRx buy the second-line StrateGIST X trial of GSK6042981 has just been unveiled and a first-line trial is to start in 2026"
X Link @ByMadeleineA 2025-10-29T10:02Z 8121 followers, 1052 engagements
"FDA has posted the approval letter for $GSK's Blemrep showing details of the REMS and postmarket study requirements"
X Link @RxRegA 2025-10-27T20:08Z 5853 followers, XXX engagements
"On $ALEC and $GSKs dementia drug fail which met a biomarker endpoint but failed to slow disease progression @cngarabedian says This speaks to the challenge of accepting biomarkers without correlative or concordance on the clinical benefit. So this is one where they say hey it did what we said it was going to do and we're seeing it on the biomarker but we just didn't see the clinical benefit play through $ALEC was one of these companies that is using a novel technology that binds to a unique region of the transferrin receptor. There have been a number of companies that people have been excited"
X Link @BiotechCH 2025-10-24T17:05Z 15.2K followers, 1177 engagements